AWHL · Aspira Women's Health Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Given the above conditions, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated interim financial statements are issued.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on May 12, 2023; bars on opposite sides are not compared.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross profit margin | 55.3% | the three months ended June 30, 2026 filing | — |
| Ova1Plus Average Unit Price (AUP) | $409 | the three months ended June 30, 2026 filing | — |
| Ova1Plus Test Volume | 3,889 | the three months ended June 30, 2026 filing | — |
| OvaWatch Average Unit Price (AUP) | $388 | the three months ended June 30, 2026 filing | — |
| OvaWatch Test Volume | 1,170 | the three months ended June 30, 2026 filing | — |
| Total OvaSuite Average Unit Price (AUP) | $402 | the three months ended June 30, 2026 filing | — |
| Total OvaSuite Test Volume | 5,059 | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AWHL
this stock
Aspira Women's Health Inc.
|
$12.12M | -58.3% | +8475.0% | — | 0.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$230.05B | +7.4% | +14.5% | 33.5 | 1.3% |
|
DHR
Danaher Corp /De/
|
$151.89B | -5.6% | +8.5% | 38.3 | 1.2% |
|
NTRA
Natera, Inc.
|
$47.03B | +42.4% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.72B | -18.0% | +10.4% | 39.0 | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- -767 sh
- Top holder
- Motiv8 Investments LLC
Performance
Raw-price comparisons begin at the captured split on May 12, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AWHL | +1.0% | -20.4% | -20.4% | -25.0% | -58.3% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +0.5% | -23.4% | -33.9% | -28.0% | -71.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.